TY  - GEN 
AU  - Roa Chamorro, Ricardo
AU  - Puerta Puerta, José Manuel
AU  - Torres Quintero, Lucía
AU  - Jaén Águila, Fernando
AU  - González Bustos, Pablo
AU  - Rodríguez‑Gil, Miguel Ángel
AU  - Mediavilla García, Juan Diego
PY  - 2023
UR  - https://hdl.handle.net/10481/95416
AB  - Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic
myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown
to have a higher risk of presenting atherosclerotic...
LA  - eng
PB  - Springer Nature
TI  - Concentration of low‑density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
DO  - 10.1038/s41598-023-39057-x
ER  -